{"contentid": 488552, "importid": NaN, "name": "Amryt Pharma buying Chiasma, to create rare diseases powerhouse", "introduction": "Irish rare diseases firm Amryt Pharma has signed a definitive agreement to acquire US-headquartered Chiasma in an all-stock combination valued at around $330 million.", "content": "<p>Irish rare diseases firm Amryt Pharma (AIM: AMYT) has signed a definitive agreement to acquire US-headquartered Chiasma (Nasdaq: CHMA) in an all-stock combination valued at around $330 million.</p>\n<p>Market reaction to the news was a &lsquo;Tale of two cities;&rsquo; Chiasma shares rocketed up more than 40% to $3.98 by close of trading on Wednesday, while Amryt dipped 2.5% and plunged a further 10.3% to 174.98 pence in early trading today.</p>\n<p>The combined company will be a global leader in rare and orphan diseases with three on-market commercial products, a global commercial and operational footprint and a significant development pipeline of therapies with the financial flexibility to execute its growth plans. The transaction has been approved and recommended by the boards of both Amryt and Chiasma. The deal expected to pave a path to a combined potential $1 billion peak revenue for Amryt.</p>\n<p>Under the terms of the transaction, each share of Chiasma common stock issued and outstanding prior to the consummation of the transaction will be exchanged for 0.396 Amryt American Depositary Shares (ADSs), each representing five Amryt ordinary shares. As of the close of trading on May 4, 2021 Amryt&rsquo;s ordinary shares on AIM were &pound;2.00 ($2.78) per share and Amryt&rsquo;s ADS&rsquo;s on Nasdaq were $12.95 (&pound;9.31) per ADS.</p>\n<h2><strong>Product portfolio</strong></h2>\n<p>The combined business will have three approved commercial products, lomitapide (Lojuxta/Juxtapid), metreleptin (Myalept/ Myalepta, octreotide (Mycapssa) and a robust clinical pipeline, with the leading investigation candidate being Oleogel-S10 (proposed trade name Filsuvez) under regulatory review in the USA and European Union to treat junctional and dystrophic epidermolysis bullosa (EB).</p>\n<p>Amryt already has in place the infrastructure, expertise and the financial flexibility to realize the full potential of Mycappsa, a treatment for in acromegaly, globally and further develop life-cycle management opportunities to expand the benefits of Mycapssa to other patient populations including NET. The transaction is expected to accelerate and diversify Amryt&rsquo;s growing revenues and Amryt expects to deliver estimated annual cost synergies of approximately $50 million.</p>\n<p>Based on the fixed exchange ratio, Amryt shareholders prior to the transaction will own around 60% of Amryt post transaction and Chiasma shareholders prior to the transaction will own about 40% of Amryt post transaction.</p>\n<h2><strong>Amryt financial guidance</strong></h2>\n<p>Separately, Amryt said it was increasing its own revenue guidance for the current year (2021) after a record first quarter. Sales rose by 8.7% to $48.4 million helped by good sales of both metreleptin and lomitapide.</p>\n<p>As a result, Amryt now predicts revenues this year will be between $205-210 million, excluding any contribution from Chiasma, which represents growth of between 12% and 15% on 2020.</p>", "date": "2021-05-06 11:13:00", "meta_title": "Amryt Pharma buying Chiasma, to create rare diseases powerhouse", "meta_keywords": "Amryt Pharma, Chiasma, Acquisition, M&A Lomitapide, Metreleptin, Mycapssa, Filsuvez", "meta_description": "Amryt Pharma buying Chiasma, to create rare diseases powerhouse", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-06 11:10:21", "updated": "2021-05-07 14:35:58", "access": NaN, "url": "https://www.thepharmaletter.com/article/amryt-pharma-buying-chiasma-to-create-rare-diseases-powerhouse", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "amryt_large_2021.jpg", "image2id": "amryt_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Rare diseases", "topic_tag": "Companies, mergers and acquisitions", "geography_tag": "Ireland, USA", "company_tag": "Amryt Pharma, Chiasma", "drug_tag": "Filsuvez, lomitapide, metreleptin, Mycapssa", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-06 11:13:00"}